Two Sigma Investments LP Has $3.41 Million Stock Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Two Sigma Investments LP raised its stake in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 71.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 371,286 shares of the medical technology company's stock after buying an additional 154,616 shares during the period. Two Sigma Investments LP owned about 0.26% of Alphatec worth $3,408,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in ATEC. Comerica Bank boosted its holdings in shares of Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock worth $29,000 after buying an additional 1,248 shares during the last quarter. R Squared Ltd bought a new position in shares of Alphatec during the 4th quarter valued at about $29,000. Nisa Investment Advisors LLC boosted its position in Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock valued at $43,000 after buying an additional 4,234 shares during the period. Quarry LP grew its holdings in Alphatec by 79.2% in the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock worth $49,000 after acquiring an additional 2,375 shares during the last quarter. Finally, Newton One Investments LLC bought a new stake in shares of Alphatec during the 4th quarter valued at about $50,000. Institutional investors and hedge funds own 66.35% of the company's stock.

Alphatec Stock Performance

Alphatec stock traded up $0.10 during midday trading on Tuesday, hitting $12.40. 69,978 shares of the company's stock were exchanged, compared to its average volume of 2,038,281. The firm's 50 day simple moving average is $11.33 and its 200 day simple moving average is $10.69. Alphatec Holdings, Inc. has a 12-month low of $4.88 and a 12-month high of $13.14. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -9.69 and a beta of 1.06.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The company had revenue of $169.18 million for the quarter, compared to analyst estimates of $167.57 million. During the same quarter last year, the company posted ($0.34) EPS. Alphatec's quarterly revenue was up 22.2% compared to the same quarter last year. Equities research analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Buying and Selling

In other Alphatec news, COO Scott Lish sold 12,000 shares of Alphatec stock in a transaction on Monday, May 5th. The stock was sold at an average price of $12.12, for a total transaction of $145,440.00. Following the sale, the chief operating officer now owns 826,251 shares of the company's stock, valued at $10,014,162.12. The trade was a 1.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David Sponsel sold 33,732 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $10.83, for a total transaction of $365,317.56. Following the sale, the executive vice president now directly owns 668,977 shares of the company's stock, valued at approximately $7,245,020.91. This represents a 4.80% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 113,798 shares of company stock valued at $1,365,665 in the last quarter. Company insiders own 20.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ATEC shares. Wall Street Zen upgraded shares of Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Needham & Company LLC reissued a "buy" rating and set a $16.00 price objective on shares of Alphatec in a research report on Friday, May 2nd. Piper Sandler reaffirmed an "overweight" rating and issued a $15.00 price objective (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a report on Monday, April 14th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.89.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.